Literature DB >> 6840925

Kinetics of low-dose intravenous antipyrine: use of liquid chromatography.

D J Greenblatt, D R Abernethy, M Divoll.   

Abstract

Rapid and sensitive quantitation of antipyrine in plasma is achieved by high-pressure liquid chromatography. Antipyrine and phenacetin, the internal standard, are readily extracted from alkalinized plasma into ethyl acetate. After evaporation of the organic solvent, the redissolved residue is chromatographed using a reverse-phase C-18 column. The sensitivity limit is approximately 0.25 micrograms antipyrine per ml plasma, with a coefficient of variation for identical samples not exceeding 3%. Using the automated sampling system, one person can analyze up to 100 samples per day. The method is reliable and sensitive enough to allow human pharmacokinetic studies of antipyrine using doses considerably less than utilized in previous studies. The disposition kinetics of a single i.v. dose of antipyrine in four human volunteers were essentially identical over a 5-fold range of doses.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6840925

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther Toxicol        ISSN: 0174-4879


  7 in total

Review 1.  Systems dynamics in clinical pharmacokinetics. An introduction.

Authors:  J M van Rossum; J E de Bie
Journal:  Clin Pharmacokinet       Date:  1989-07       Impact factor: 6.447

2.  Interaction between vigabatrin and phenytoin.

Authors:  E M Rimmer; A Richens
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

3.  Simplified approaches to the determination of antipyrine pharmacokinetic parameters.

Authors:  J M Scavone; D J Greenblatt; G T Blyden; J S Harmatz; P J Graziano
Journal:  Br J Clin Pharmacol       Date:  1988-06       Impact factor: 4.335

4.  Effect of antipyrine coadministration on the kinetics of acetaminophen and lidocaine.

Authors:  G T Blyden; D J Greenblatt; B W LeDuc; J M Scavone
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 5.  Quantifying hepatic function in the presence of liver disease with phenazone (antipyrine) and its metabolites.

Authors:  J V St Peter; W M Awni
Journal:  Clin Pharmacokinet       Date:  1991-01       Impact factor: 6.447

6.  Lack of effect of influenza vaccine on the pharmacokinetics of antipyrine, alprazolam, paracetamol (acetaminophen) and lorazepam.

Authors:  J M Scavone; G T Blyden; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  1989-03       Impact factor: 6.447

7.  Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine.

Authors:  L L von Moltke; D J Greenblatt; M M Cotreau-Bibbo; J S Harmatz; R I Shader
Journal:  Br J Clin Pharmacol       Date:  1994-07       Impact factor: 4.335

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.